Vanda Pharmaceuticals announces positive Phase III results for Hetlioz in delayed sleep-wake phase disorder
VNDA•Vanda Pharmaceuticals said a Phase III study of Hetlioz met its primary endpoint, with a 37.1-minute sleep-onset shift versus placebo. No new safety signals were identified.
1. Phase III results
Vanda Pharmaceuticals announced positive Phase III results for Hetlioz (tasimelteon) in delayed sleep-wake phase disorder. The study met its primary endpoint, with a 37.1-minute sleep-onset shift versus placebo, and identified no new safety signals.
